Recombinant SARS-CoV-2 Spike S1 抗体
Quick Overview for Recombinant SARS-CoV-2 Spike S1 抗体 (ABIN7566483)
抗原
See all SARS-CoV-2 Spike S1 抗体抗体类型
适用
宿主
克隆类型
标记
应用范围
克隆位点
-
-
原理
- anti-SARS-CoV-2 Spike Protein S1 (RBD), mAb (rec.) (AB65-3-G12)
-
产品特性
-
Recombinant Antibody. Recognizes the SARS-CoV-2 S1 (Receptor-binding domain). Does not cross-react with HCoV-OC43, HCoV-229E, HCoV-NL63, HCoV-HKU1, MERS-CoV or SARS-CoV. Applications: ELISA. Clone: AB65-3-G12. Isotype: Mouse IgG2a. Formulation: Liquid. In PBS. Coronaviruses (CoVs) are enveloped non-segmented positive-sense single-stranded RNA viruses and can infect respiratory, gastrointestinal, hepatic and central nervous system of human and many other wild animals. Recently, a new severe acute respiratory syndrome beta-coronavirus called SARS-CoV-2 (or 2019-nCoV) has emerged, which causes an epidemic of acute respiratory syndrome (called coronavirus human disease 2019 or COVID-19). SARS-CoV-2 shares 79.5 % sequence identity with SARS-CoV and is 96.2 % identical at the genome level to the bat coronavirus BatCoV RaTG133, suggesting it had originated in bats. SARS-CoV-2 contains 4 structural proteins, including Envelope (E), Membrane (M), Nucleocapsid (N) and Spike (S), which is a transmembrane protein, composed of two subunits S1 and S2. The S protein plays a key role in viral infection and pathogenesis. The S1 subunit contains the N-terminal domain (NTD) and a receptor binding domain (RBD), which binds to the cell surface receptor Angiotensin-Converting Enzyme 2 (ACE2) present at the surface of epithelial cells, causing mainly infection of human respiratory cells, whereas S2 harbors heptad repeat 1 (HR1) and HR2. The RBD domain first binds its receptor to form an RBD/ACE2 complex. This triggers conformational changes in the S protein, leading to membrane fusion mediated via HR1 and HR2 and consequently in viral entry into target cells. Antibodies targeting various regions of S protein have different mechanisms in inhibiting SARS-CoV-2 infection. For example, NTD-targeting antibodies bind the NTD to form an NTD/mAb complex, thereby preventing conformational changes in the S protein and blocking membrane fusion and viral entry. RBD-targeting antibodies form RBD/mAb or RBD/Nb complexes that inhibit binding of the RBD to ACE2, thereby preventing entry of SARS-CoV-2 into target cells.
Coronaviruses (CoVs) are enveloped non-segmented positive-sense single-stranded RNA viruses and can infect respiratory, gastrointestinal, hepatic and central nervous system of human and many other wild animals. Recently, a new severe acute respiratory syndrome beta-coronavirus called SARS-CoV-2 (or 2019-nCoV) has emerged, which causes an epidemic of acute respiratory syndrome (called coronavirus human disease 2019 or COVID-19). SARS-CoV-2 shares 79.5 % sequence identity with SARS-CoV and is 96.2 % identical at the genome level to the bat coronavirus BatCoV RaTG133, suggesting it had originated in bats. SARS-CoV-2 contains 4 structural proteins, including Envelope (E), Membrane (M), Nucleocapsid (N) and Spike (S), which is a transmembrane protein, composed of two subunits S1 and S2. The S protein plays a key role in viral infection and pathogenesis. The S1 subunit contains the N-terminal domain (NTD) and a receptor binding domain (RBD), which binds to the cell surface receptor Angiotensin-Converting Enzyme 2 (ACE2) present at the surface of epithelial cells, causing mainly infection of human respiratory cells, whereas S2 harbors heptad repeat 1 (HR1) and HR2. The RBD domain first binds its receptor to form an RBD/ACE2 complex. This triggers conformational changes in the S protein, leading to membrane fusion mediated via HR1 and HR2 and consequently in viral entry into target cells. Antibodies targeting various regions of S protein have different mechanisms in inhibiting SARS-CoV-2 infection. For example, NTD-targeting antibodies bind the NTD to form an NTD/mAb complex, thereby preventing conformational changes in the S protein and blocking membrane fusion and viral entry. RBD-targeting antibodies form RBD/mAb or RBD/Nb complexes that inhibit binding of the RBD to ACE2, thereby preventing entry of SARS-CoV-2 into target cells.
-
纯化方法
- Puified
-
纯度
- >95 % (SDS-PAGE)
-
免疫原
- Recombinant SARS-CoV-2 S1 Protein (aa 14-682) containing a C-terminal human Fc-tag.
-
亚型
- IgG2a
-
-
-
-
应用备注
- Optimal working dilution should be determined by the investigator.
-
限制
- 仅限研究用
-
-
-
状态
- Liquid
-
浓度
- 1 mg/mL
-
缓冲液
- In PBS.
-
注意事项
- After opening, prepare aliquots and store at -20 °C.Avoid freeze/thaw cycles.Please handle under sterile conditions to avoid contamination.
-
储存条件
- 4 °C,-20 °C
-
储存方法
-
Stable for at least 1 year after receipt when stored at -20°C.
Stable for at least 3 months after receipt when stored at +4°C.
-
-
- SARS-CoV-2 Spike S1
-
别名
- SARS-CoV-2 Spike Protein S1
抗原
-